• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Sci Adv . Repetitive mRNA vaccination is required to improve the quality of broad-spectrum anti-SARS-CoV-2 antibodies in the absence of CXCL13

tetano

Editor, Senior Moderator
Sci Adv


. 2023 Aug 4;9(31):eadg2122.
doi: 10.1126/sciadv.adg2122. Epub 2023 Aug 4. Repetitive mRNA vaccination is required to improve the quality of broad-spectrum anti-SARS-CoV-2 antibodies in the absence of CXCL13

Marne Azarias Da Silva[SUP] 1 [/SUP], Pierre Nioche[SUP] 1 2 [/SUP], Calaiselvy Soudaramourty[SUP] 1 [/SUP], Anne Bull-Maurer[SUP] 3 [/SUP], Mounira Tiouajni[SUP] 1 2 [/SUP], Dechuan Kong[SUP] 4 5 [/SUP], Ouafa Zghidi-Abouzid[SUP] 6 [/SUP], Morgane Picard[SUP] 1 [/SUP], Ana Mendes-Frias[SUP] 7 8 [/SUP], André Santa-Cruz[SUP] 7 8 9 [/SUP], Alexandre Carvalho[SUP] 7 8 9 [/SUP], Carlos Capela[SUP] 7 8 9 [/SUP], Jorge Pedrosa[SUP] 7 8 [/SUP], António Gil Castro[SUP] 7 8 [/SUP], Paul Loubet[SUP] 10 [/SUP], Albert Sotto[SUP] 10 [/SUP], Laurent Muller[SUP] 11 [/SUP], Jean-Yves Lefrant[SUP] 11 [/SUP], Claire Roger[SUP] 11 [/SUP], Pierre-Géraud Claret[SUP] 12 [/SUP], Sandra Duvnjak[SUP] 13 [/SUP], Tu-Anh Tran[SUP] 14 [/SUP], Kenzo Tokunaga[SUP] 5 [/SUP], Ricardo Silvestre[SUP] 7 8 [/SUP], Pierre Corbeau[SUP] 15 16 [/SUP], Fabrizio Mammano[SUP] 1 3 [/SUP], Jérôme Estaquier[SUP] 1 6 [/SUP]



Affiliations
Abstract

Since the initial spread of severe acute respiratory syndrome coronavirus 2 infection, several viral variants have emerged and represent a major challenge for immune control, particularly in the context of vaccination. We evaluated the quantity, quality, and persistence of immunoglobulin G (IgG) and IgA in individuals who received two or three doses of messenger RNA (mRNA) vaccines, compared with previously infected vaccinated individuals. We show that three doses of mRNA vaccine were required to match the humoral responses of preinfected vaccinees. Given the importance of antibody-dependent cell-mediated immunity against viral infections, we also measured the capacity of IgG to recognize spike variants expressed on the cell surface and found that cross-reactivity was also strongly improved by repeated vaccination. Last, we report low levels of CXCL13, a surrogate marker of germinal center activation and formation, in vaccinees both after two and three doses compared with preinfected individuals, providing a potential explanation for the short duration and low quality of Ig induced.


 
Back
Top Bottom